Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model

Autor: Maguire, SL, Peck, B, Wai, PT, Campbell, J, Barker, H, Gulati, A, Daley, F, Vyse, S, Huang, P, Lord, CJ, Farnie, G, Brennan, K, Natrajan, R

Publikováno v: Maguire, S L, Peck, B, Wai, P T, Campbell, J, Barker, H, Gulati, A, Daley, F, Vyse, S, Huang, P, Lord, C J, Farnie, G, Brennan, K & Natrajan, R 2016, ' Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model ', Journal of Pathology, vol. 240, no. 3, pp. 315-328 . https://doi.org/10.1002/path.4778
The Journal of Pathology

The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal carcinoma in situ (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations and changes in gene express

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5821b0895a913f53df3cec7924292b1d
https://doi.org/10.1002/path.4778

SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.

Autor: Bland P; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Saville H; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Wai PT; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Curnow L; Division of Cancer Biology, The Institute of Cancer Research, London, UK., Muirhead G; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Nieminuszczy J; Division of Cancer Biology, The Institute of Cancer Research, London, UK., Ravindran N; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., John MB; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Hedayat S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Barker HE; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Wright J; Division of Cancer Biology, The Institute of Cancer Research, London, UK., Yu L; Division of Cancer Biology, The Institute of Cancer Research, London, UK., Mavrommati I; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Read A; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Peck B; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; Translational Cancer Metabolism Team, Centre for Tumour Biology, Barts Cancer Institute, Cancer Research UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London, UK., Allen M; Biological Services Unit, The Institute of Cancer Research, London, UK., Gazinska P; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Pemberton HN; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, UK., Gulati A; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, UK., Nash S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Noor F; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Guppy N; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Roxanis I; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Pratt G; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Oldreive C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Stankovic T; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Barlow S; Liverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK., Kalirai H; Liverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK., Coupland SE; Liverpool Ocular Oncology Research Group, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK., Broderick R; Division of Cancer Biology, The Institute of Cancer Research, London, UK., Alsafadi S; Inserm U830, PSL University, Institut Curie, Paris, France., Houy A; Inserm U830, PSL University, Institut Curie, Paris, France., Stern MH; Inserm U830, PSL University, Institut Curie, Paris, France., Pettit S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, UK., Choudhary JS; Division of Cancer Biology, The Institute of Cancer Research, London, UK., Haider S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Niedzwiedz W; Division of Cancer Biology, The Institute of Cancer Research, London, UK., Lord CJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, UK., Natrajan R; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. rachael.natrajan@icr.ac.uk.

Publikováno v: Nature genetics [Nat Genet] 2023 Aug; Vol. 55 (8), pp. 1311-1323. Date of Electronic Publication: 2023 Jul 31.

High specific surface CeO 2 -NPs doped loose porous C 3 N 4 for enhanced photocatalytic oxidation ability.

Autor: Gu Q; Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, People's Republic of China., Jiang P; Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, People's Republic of China., Zhang K; Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, People's Republic of China., Shen Y; College of Materials and Chemical Engineering, Ningbo University of Technology, Ningbo 315211, People's Republic of China., Leng Y; Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, People's Republic of China., Zhang P; Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, People's Republic of China., Wai PT; Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, People's Republic of China., Yu J; Hairma (Nantong) Technology Co., Ltd, Nantong, 226000, People's Republic of China., Cao Z; Hairma (Nantong) Technology Co., Ltd, Nantong, 226000, People's Republic of China.

Publikováno v: Nanotechnology [Nanotechnology] 2022 Mar 15; Vol. 33 (23). Date of Electronic Publication: 2022 Mar 15.

3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.

Autor: Peck B; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom., Bland P; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom., Mavrommati I; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom., Muirhead G; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Cottom H; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom., Wai PT; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom., Maguire SL; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom., Barker HE; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Division of Stem Cells and Cancer, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia., Morrison E; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Kriplani D; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Yu L; Division of Cancer Biology, The Institute of Cancer Research, London, England, United Kingdom., Gibson A; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom., Falgari G; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom., Brennan K; Faculty of Life Sciences, University of Manchester, Manchester, England, United Kingdom., Farnie G; SGC Oxford, University of Oxford, Oxford, England, United Kingdom., Buus R; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Marlow R; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Breast Cancer Now Research Unit, King's College London, London, England, United Kingdom., Novo D; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Knight E; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Guppy N; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Kolarevic D; The Royal Marsden NHS Foundation Trust, London, England, United Kingdom., Susnjar S; Department of Medical Oncology, The Institute of Oncology and Radiology of Serbia, Belgrade, Serbia., Milijic NM; Department of Pathology and Cytology, The Institute of Oncology and Radiology of Serbia, Belgrade, Serbia., Naidoo K; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Gazinska P; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Roxanis I; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Pancholi S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Martin LA; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Holgersen EM; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Cheang MCU; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, England, United Kingdom., Noor F; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Postel-Vinay S; Department of Drug Development (DITEP), Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.; UMR981, ATIP-Avenir team, INSERM, Villejuif, France., Quinn G; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom., McDade S; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom., Krasny L; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom., Huang P; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom., Daley F; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Wallberg F; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Choudhary JS; Division of Cancer Biology, The Institute of Cancer Research, London, England, United Kingdom., Haider S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom., Tutt AN; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom.; Breast Cancer Now Research Unit, King's College London, London, England, United Kingdom., Natrajan R; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England, United Kingdom. rachael.natrajan@icr.ac.uk.; Division of Molecular Pathology, The Institute of Cancer Research, London, England, United Kingdom.

Publikováno v: Cancer research [Cancer Res] 2021 Feb 15; Vol. 81 (4), pp. 847-859. Date of Electronic Publication: 2021 Jan 28.

Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.

Autor: Naidoo K; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom., Wai PT; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.; Division of Molecular Pathology, Centre for Evolution and Cancer and Centre for Molecular Pathology, The Institute of Cancer Research, London, United Kingdom., Maguire SL; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom., Daley F; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom., Haider S; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom., Kriplani D; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom., Campbell J; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Mirza H; Cancer Bioinformatics, Cancer Division, King's College London, London, United Kingdom., Grigoriadis A; Cancer Bioinformatics, Cancer Division, King's College London, London, United Kingdom., Tutt A; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.; Breast Cancer Now Research Unit, King's College London, London, United Kingdom., Moseley PM; Clinical Oncology, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom., Abdel-Fatah TMA; Clinical Oncology, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom., Chan SYT; Clinical Oncology, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom., Madhusudan S; Department of Histopathology and Division of Cancer & Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom., Rhaka EA; Department of Histopathology and Division of Cancer & Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom., Ellis IO; Department of Histopathology and Division of Cancer & Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom., Lord CJ; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.; The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom., Yuan Y; Division of Molecular Pathology, Centre for Evolution and Cancer and Centre for Molecular Pathology, The Institute of Cancer Research, London, United Kingdom., Green AR; Department of Histopathology and Division of Cancer & Stem Cells, School of Medicine, The University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, United Kingdom., Natrajan R; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom. rachael.natrajan@icr.ac.uk.; Division of Molecular Pathology, Centre for Evolution and Cancer and Centre for Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2018 Jan; Vol. 17 (1), pp. 306-315. Date of Electronic Publication: 2017 Nov 13.